Odd Harmonious Labeling of Some Graphs

The labeling of discrete structures is a potential area of research due to its wide range of applications. The present work is focused on one such labeling called odd harmonious labeling

Influence of TNF Alpha on Testosterone Induced Cardiac Effects in Isolated Frog Heart Model

The effect of Tumor necrosis factor-alpha and testosterone was evaluated on the isolated Rana tigrina frog heart. The isolated frog heart (n= 10) were used for this study and the effect of drugs on myocardial contractility and heart rate was ascertained. Namely three drugs testosterone (4mg), bicalutamide (8mg) and TNF-alpha antagonist infliximab (0.4mg) were utilized for this study. Testosterone caused an increase in heart rate by 11.28% and decrease in myocardial contractility by 17.67%. Similarly bicalutamide caused a 20.11% decrease Heart rate and 41.17% decrease in myocardial contractility. To ascertain the role of TNF-alpha, infliximab was perfused through the heart and it potentiated the inhibitory effect of testosterone on the myocardial contractility and heart rate. The results of this study suggest the importance of TNF-alpha and testosterone hormone in cardiovascular pathophysiology

Study of starch degrading bacteria from kitchen waste soil in the production of amylase by using paddy straw

The starch degrading amylolytic enzymes are of crucial importance in biotechnology industries with huge application in food, fermentation, textile and paper production. They are universally distribution in bacteria and fungus. Present study aimed at production of pure form of α-amylase from kitchen waste soil with optimization of raw material such as carbon and nitrogen source of the culture media for it. Objective: To evaluate the kitchen waste soil for production of α-amylase with optimization of carbon and nitrogen source required for culture media. Method: The starch degrading bacteria was isolated from the kitchen waste soil environment and was used for production of α-amylase through submerged. The paddy straw extract was shown the best source of carbon and potassium nitrate as the best source of nitrogen with optimum pH 7.0 and temperature of 30ºC. The fermentor parameters were set with the agitator at speed 200rpm with 100% dissolved O2 at fixed temperature and pH. After completion of the fermentation process, the activity of the enzyme was checked by the DNS method. Results: Enzyme produced and purified by this method, was found to have an enzymatic activity of 0.51 mg/ml after column chromatography by nanodrop spectrophotometer and coincide with standard in SDS-PAGE. Here, we have shown the cheap method of commercial production of economically valuable amylase by utilizing paddy straw

D* Production in Deep Inelastic Scattering at HERA

This paper presents measurements of D^{*\pm} production in deep inelastic scattering from collisions between 27.5 GeV positrons and 820 GeV protons. The data have been taken with the ZEUS detector at HERA. The decay channel $D^{*+}\to (D^0 \to K^- \pi^+) \pi^+$ (+ c.c.) has been used in the study. The $e^+p$ cross section for inclusive D^{*\pm} production with $5<Q^2<100 GeV^2$ and $y<0.7$ is 5.3 \pms 1.0 \pms 0.8 nb in the kinematic region {$1.3<p_T(D^{*\pm})<9.0$ GeV and $| \eta(D^{*\pm}) |<1.5$}. Differential cross sections as functions of p_T(D^{*\pm}), $\eta(D^{*\pm}), W$ and $Q^2$ are compared with next-to-leading order QCD calculations based on the photon-gluon fusion production mechanism. After an extrapolation of the cross section to the full kinematic region in p_T(D^{*\pm}) and $\eta$(D^{*\pm}), the charm contribution $F_2^{c\bar{c}}(x,Q^2)$ to the proton structure function is determined for Bjorken $x$ between 2 $\cdot$ 10$^{-4}$ and 5 $\cdot$ 10$^{-3}$.Comment: 17 pages including 4 figure

Observation of Scaling Violations in Scaled Momentum Distributions at HERA

Charged particle production has been measured in deep inelastic scattering (DIS) events over a large range of $x$ and $Q^2$ using the ZEUS detector. The evolution of the scaled momentum, $x_p$, with $Q^2,$ in the range 10 to 1280 $GeV^2$, has been investigated in the current fragmentation region of the Breit frame. The results show clear evidence, in a single experiment, for scaling violations in scaled momenta as a function of $Q^2$.Comment: 21 pages including 4 figures, to be published in Physics Letters B. Two references adde

Observation of hard scattering in photoproduction events with a large rapidity gap at HERA

Events with a large rapidity gap and total transverse energy greater than 5 GeV have been observed in quasi-real photoproduction at HERA with the ZEUS detector. The distribution of these events as a function of the $\gamma p$ centre of mass energy is consistent with diffractive scattering. For total transverse energies above 12 GeV, the hadronic final states show predominantly a two-jet structure with each jet having a transverse energy greater than 4 GeV. For the two-jet events, little energy flow is found outside the jets. This observation is consistent with the hard scattering of a quasi-real photon with a colourless object in the proton.Comment: 19 pages, latex, 4 figures appended as uuencoded fil

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

BACKGROUND: Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia. METHODS: We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed. FINDINGS: Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia\u27s formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [&lt;1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died within the study treatment period, including the 30-day follow-up. 18 (5%) patients died because of an adverse event considered by the investigator to be treatment related (ten [6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2. INTERPRETATION: Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses. FUNDING: Ambit Biosciences/Daiichi Sankyo

Development of lanthanum strontium cobalt ferrite composite cathodes for intermediate- to low-temperature solid oxide fuel cells

Solid oxide fuel cells (SOFCs) offer high energy conversion, low noise, low pollutant emission, and low processing cost. Despite many advantages, SOFCs face a major challenge in competing with other types of fuel cells because of their high operating temperature. The necessity to reduce the operational temperature of SOFCs has led to the development of research into the materials and fabrication technology of fuel cells. The use of composite cathodes significantly reduces the cathode polarization resistance and expands the triple phase boundary area available for oxygen reduction. Powder preparation and composite cathode fabrication also affect the overall performance of composite cathodes and fuel cells. Among many types of cathode materials, lanthanum-based materials such as lanthanum strontium cobalt ferrite (La1-xSrxCo1-yFeyO3-δ) have recently been discovered to offer great compatibility with ceria-based electrolytes in performing as composite cathode materials for intermediate- to low-temperature SOFCs (IT-LTSOFCs). This paper reviews various ceria-based composite cathodes for IT-LTSOFCs and focuses on the aspects of progress and challenges in materials technology